提醒公司访问IONS -提醒美国东部时间今日上午11点-巴克莱与高级管理层的科学电话会议系列

confirmed calls so far, which we will update as we are able to finalize dates for others.Following each call, we will provide key takeaways as well as replays/transcripts.Current Schedule•Fri, Apr 25, 2025, 12:00 PM ET – RARE, Emil Kakkis, President & CEO••Fri, May 9, 2025, 11:00 AM ET – BMRN, Greg Friberg, EVP, Chief R&DOfficer;Brian Mueller,•EVP, CFO•Thu, May 22, 2025, 11:00 AM ET – IONS, Brett Monia, CEO;Eric Swayze, EVP,•Research•Fri, May 23, 2025, 9:00 AM ET – ALNY, Kevin Fitzgerald, CSO; Tolga Tanguler, CCO••Thu, May 29, 2025, 10:00 AM ET – VRTX, David Altshuler, EVP, CSO••Thu, Jun 5, 2025, 10:00 AM ET – LEGN, Ying Huang, CEO••Fri, Jun 6, 2025,11:00 AM ET – SRPT, Doug Ingram, President & CEO; Louise Rodino-•Klapac, Head of R&D, CSO•Fri, Jun 13, 2025, 11:00 AM ET – BEAM, John Evans, CEO; Giuseppe Ciaramella, President••Mon, Jun 16, 2025, 10:00 AM ET – MRNA, Rose Loughlin, EVP, Research; Lavina Talukdar,•SVP, IR•Fri, Jun 20, 2025, 12:00 PM ET – RNA, Steve Hughes, CMO; Mike Flanagan, CSO•Relevant Research•RARE - Key takeaways from Barclays Speaking the Science Conference Call, 04/25/2025;•Replay and Transcript: RARE - Barclays Speaking the Science Call, 04/28/2025.•BMRN - Key takeaways from Barclays Speaking the Science Conference Call, 05/11/2025;•Replay and Transcript: BMRN - Barclays Speaking the Science Call, 05/12/2025.Meet the AnalystGena Wang PhD, CFA, is an equity research analystcovering U.S. Small & Mid Cap Biotechnology and hasbeen ranked top 3 in the sector by Institutional Investorsince 2018 (except 2020 RU). She has sell-side experiencesince 2009 and before her career on Wall Street hadextensive scientific research experience and publishednumerous peer-reviewed papers. Gena was a Post-Doctoral Researcher in Molecular Neuro-oncology atRockefeller University and received her PhD in MolecularBiology from SUNY Downstate Medical Center. Gena Wang, PhD, CFA+1 212 526 4252BCI, USU.S. Small & Mid Cap BiotechnologyThis event is intended for Barclays institutional investor clients only. This event is strictly and solelyfor the benefit of the intended recipients. Please do not forward this invitation to any other partywithout written consent from Barclays Research. Barclays' Investment Bankers are prohibited fromattending this event. Participant comments are not for attribution.If your firm is in-scope for research unbundling under MiFID II and you require further informationregarding pricing to participate in this Barclays Research content event, please contact your salesrepresentative.Barclays Capital Inc. and/or one of itsaffiliatesdoes and seeks to do business with companies coveredin its research reports. As a result, investors should be aware that the firm may have a conflict ofinterest that couldaffectthe objectivity of this report. Investors should consider this report as only asingle factor in making their investment decision.Any views or opinions by Barclays research analysts have been previously published in researchreports available to our clients on Barclays Live. Click here to view the guide to the Barclaysfundamental equity research rating system.For analyst certifications and important disclosures including, where applicable, foreignaffiliatedisclosures, and the date and time when the production of each recommendation was completed andfirst disseminated, please refer to the full document(s) included in this email or go to our Researchportal on Barclays Live. To access conflict of interest disclosures relating to issuers covered byBarclays Research, please see https://publicresearch.barclays.com.Barclays Events Terms of Service | Barclays Events Privacy NoticeDisclaimer:BARCLAYSThis communication has been prepared by Barclays.“Barclays” means any entity within the Barclays Group of companies, where “Barclays Group” meansBarclays Bank PLC, Barclays PLC and any of their subsidiaries,affiliates,ultimate holding companyand any subsidiaries oraffiliatesof such holding company.CONFLICTS OF INTERESTBARCLAYS IS A FULL SERVICE INVESTMENT BANK. In the normal course ofofferinginvestment bankingproducts and services to clients, Barclays may act in several capacities (including issuer, marketmaker and/or liquidity provider, underwriter, distributor, index sponsor, swap counterparty andcalculation agent) simultaneously with respect to a product, giving rise to potential conflicts ofinterest which may impact the performance of a product.BARCLAYS POSITIONSBarclays may at any time acquire, hold or dispose of long or short positions (including hedging andtrading positions) and trade or otherwiseeffecttransactions for their own account or the account oftheir customers in the products referred to herein which may impact the performance of a product.FOR INFORMATION ONLYTHIS DOCUMENT IS PROVIDED FOR INFORMATION PURPOSES ONLY AND IT IS SUBJECT TO CHANGE.This information has been prepared by the Research Department within the Investment Bank of Barclays. The information, analytic tools, and/or models referen